Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07170059

Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients

To evaluate the impact of herpes zoster vaccine on the incidence of herpes zoster and survival in lung cancer patients, and to explore its preventive effect and safety.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1.Male or female patients >=18 years of age; 2.Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments; 3. Never received herpes zoster vaccine

Exclusion criteria

  • Patients having other factors that preventing researchers from enrollment them.

Treatment and study plan

herpes zoster vaccine

Biological

Receive the herpes zoster vaccine; Do not receive the herpes zoster vaccine

Primary outcomes

  1. The incidence of herpes zoster at 12 months

    Time frame: 12 months

    During the 12-month follow-up period, the incidence of herpes zoster in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests.

  2. Incidence of herpes zoster

    Time frame: 24 months

    The proportion of lung cancer patients who developed herpes zoster during the study period.

Secondary outcomes

  1. Survival rate

    Time frame: 5 years

    The survival rate of lung cancer patients within a specific time period (such as 1 year, 2 years, or 5 years).

Other outcomes

  1. Lung cancer-related complications

    Time frame: 5 years

    Severity of herpes zoster and incidence of complications (e.g., postherpetic neuralgia)

  2. Length of hospital stay

    Time frame: 5 years

    Record the number of days of hospitalization for patients hospitalized due to herpes zoster

  3. Hospitalization rate

    Time frame: 5 years

    The proportion of patients hospitalized due to herpes zoster or other related complications.

  4. Immune response

    Time frame: 5 years

    The immune response (such as antibody levels) of patients after vaccination is evaluated through serological testing.

  5. Adverse reactions after vaccination

    Time frame: 30 days

    Observe whether patients who receive the herpes zoster vaccine experience adverse reactions after vaccination, such as fever, redness, swelling and pain at the injection site, headache, dizziness, etc.

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital of Guangzhou Medical University

Other

Registry information

Official study title

An Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients

Important dates

Study start
2025
Primary completion
2026
Study completion
2030
First posted
Sep 12, 2025
Registry last updated
Sep 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.